The menopause transition carries a 2-fold increased risk of depression, and an expert explains how clinicians can screen for it, tell it apart from other conditions, and treat it.
Despite previous failure of PDE10A inhibitor drugs to demonstrate antipsychotic effects in clinical trials, a new "improved" iteration has met phase 2 trial endpoints.